Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19

Author(s): Saeid Azimi, Fatemeh Saghafi, Mohammad Hossein Mohammadi, Mohammad Hossein Moghimi, Seyed Ali Akhavan, Masoud Khataminia, Maria Shirvani, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh* and Amirhossein Sahebkar*

Volume 29, Issue 29, 2023

Published on: 02 October, 2023

Page: [2291 - 2296] Pages: 6

DOI: 10.2174/0113816128275803230920094909

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

COVID-19 disease manifests itself in a wide range of signs and symptoms, beginning with mild symptoms, such as fever, cough, and dyspnea, progressing to acute respiratory distress syndrome (ARDS) and death in some cases. The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 patients, early management of the cytokine storm with immunomodulators is crucial. Although the effectiveness of some immunosuppressants, such as corticosteroids and tocilizumab, has been studied in clinical trials, the administration of these drugs should be exercised cautiously. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid from Cannabis sativa extracts with anti-inflammatory properties. This review is intended to discuss the possible utility of CBD for the management of COVID-19 patients, particularly those with ARDS.

Keywords: COVID-19, acute respiratory distress syndrome, cytokine, survival rate, immunosuppressant, cannabidiol.

« Previous Next »
[1]
Segreto R, Deigin Y, McCairn K, Sousa A, Sirotkin D, Sirotkin K. Should we discount the laboratory origin of COVID-19? Springer 2021.
[http://dx.doi.org/10.1007/s10311-021-01211-0]
[2]
Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res 2020; 188: 109819.
[http://dx.doi.org/10.1016/j.envres.2020.109819] [PMID: 32569870]
[3]
Vetter P, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of COVID-19. BMJ 2020; 369: m1470.
[http://dx.doi.org/10.1136/bmj.m1470]
[4]
Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov 2020; 6(1): 83.
[http://dx.doi.org/10.1038/s41421-020-00231-4] [PMID: 33298875]
[5]
Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021; 16(3): e0247461.
[http://dx.doi.org/10.1371/journal.pone.0247461] [PMID: 33661992]
[6]
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm 2021; 18(3): 754-71.
[7]
Williams H, Hutchinson D, Stone H. Watching Brief: The evolution and impact of COVID-19 variants B.1.1.7, B.1.351, P.1 and B.1.617. Global Biosecur 2021; 3.
[8]
Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti-infective Therapy 2021; 19(3): 345-357.
[http://dx.doi.org/10.1080/14787210.2020.1822737]
[9]
Grove J, Marsh M. The cell biology of receptor-mediated virus entry. J Cell Biol 2011; 195(7): 1071-82.
[http://dx.doi.org/10.1083/jcb.201108131] [PMID: 22123832]
[10]
Mathewson AC, Bishop A, Yao Y, et al. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J Gen Virol 2008; 89(11): 2741-5.
[http://dx.doi.org/10.1099/vir.0.2008/003962-0] [PMID: 18931070]
[11]
Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26(5): 681-7.
[http://dx.doi.org/10.1038/s41591-020-0868-6] [PMID: 32327758]
[12]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-80.e8.
[13]
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176: 104742.
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[14]
Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. COVID-19 infection and mortality: A physiologist’s perspective enlightening clinical features and plausible interventional strategies. Am J Physiol Lung Cell Mol Physiol 2020; 318(5): L1020-2.
[http://dx.doi.org/10.1152/ajplung.00097.2020] [PMID: 32207983]
[15]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[16]
Sahebnasagh A, Nabavi SM, Kashani HRK, Abdollahian S, Habtemariam S, Rezabakhsh A. Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients. Int Immunopharmacol 2021; 101(Pt B): 108257.
[http://dx.doi.org/10.1016/j.intimp.2021.108257] [PMID: 34673299]
[17]
Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020; 19(5): 102523.
[http://dx.doi.org/10.1016/j.autrev.2020.102523] [PMID: 32205186]
[18]
Charytoniuk T, Sztolsztener K, Harasim-Symbor E, Berk K, Chabowski A, Konstantynowicz-Nowicka K. Cannabidiol – A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance. Biomed Pharmacother 2021; 142: 112057.
[http://dx.doi.org/10.1016/j.biopha.2021.112057] [PMID: 34435590]
[19]
Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci 2000; 97(17): 9561-6.
[http://dx.doi.org/10.1073/pnas.160105897] [PMID: 10920191]
[20]
Verrico CD, Wesson S, Konduri V, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain 2020; 161(9): 2191-202.
[http://dx.doi.org/10.1097/j.pain.0000000000001896] [PMID: 32345916]
[21]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[22]
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46(5): 846-8.
[http://dx.doi.org/10.1007/s00134-020-05991-x] [PMID: 32125452]
[23]
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2020. Available from: https://www.covid19treatmentguidelines.nih.gov
[24]
Marik J, Varon J, Gathe J. UMMC. EVMS critical care COVID-19 management protocol. Available from: https://www.sbk-vs.de/images/pdf/downloads/Corona/EVMS_Critical_Care_COVID-19_Protocol.pdf
[25]
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215: 108448.
[http://dx.doi.org/10.1016/j.clim.2020.108448] [PMID: 32353634]
[26]
Na-Bangchang K, Porasuphatana S, Karbwang J. Perspective: Repurposed drugs for COVID-19. Arch Med Sci: AMS, 2022; 18(5): 1378-1391.
[http://dx.doi.org/10.5114/aoms/152467]
[27]
Esposito G, Pesce M, Seguella L, et al. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol 2020; 177(21): 4967-70.
[http://dx.doi.org/10.1111/bph.15157] [PMID: 32519753]
[28]
Nagarkatti P, Miranda K, Nagarkatti M. Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with Coronavirus disease-2019. Front Pharmacol 2020; 11: 589438.
[http://dx.doi.org/10.3389/fphar.2020.589438] [PMID: 33240092]
[29]
Malinowska B, Baranowska-Kuczko M, Kicman A, Schlicker E. Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19. Int J Mol Sci 2021; 22(4): 1986.
[http://dx.doi.org/10.3390/ijms22041986] [PMID: 33671463]
[30]
Ketha H, Garg U. Cannabinoids. Toxicology Cases for the Clinical and Forensic Laboratory: Elsevier 2020; pp. 169-76.
[31]
Costiniuk CT, Jenabian MA. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Cytokine Growth Factor Rev 2020; 53: 63-5.
[http://dx.doi.org/10.1016/j.cytogfr.2020.05.008] [PMID: 32467020]
[32]
Salles ÉL, Khodadadi H, Jarrahi A, et al. Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. J Cell Mol Med 2020; 24(21): 12869-72.
[http://dx.doi.org/10.1111/jcmm.15883] [PMID: 33058425]
[33]
Peyravian N, Deo S, Daunert S, Jimenez JJ. Cannabidiol as a novel therapeutic for immune modulation. ImmunoTargets Ther 2020; 9: 131-40.
[http://dx.doi.org/10.2147/ITT.S263690] [PMID: 32903924]
[34]
Numata T, Takahashi K, Inoue R, Eds. “TRP inflammation” relationship in cardiovascular system Seminars in immunopathology. Springer 2016.
[35]
Khajavi N, Mergler S, Biebermann H. 3-Iodothyronamine, a novel endogenous modulator of transient receptor potential melastatin 8? Front Endocrinol 2017; 8: 198.
[http://dx.doi.org/10.3389/fendo.2017.00198] [PMID: 28861042]
[36]
Schwingshackl A. The role of stretch-activated ion channels in acute respiratory distress syndrome: finally a new target? Am J Physiol Lung Cell Mol Physiol 2016; 311(3): L639-52.
[http://dx.doi.org/10.1152/ajplung.00458.2015] [PMID: 27521425]
[37]
Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004; 143(2): 247-50.
[http://dx.doi.org/10.1038/sj.bjp.0705920] [PMID: 15313881]
[38]
Fonseca BM, Correia-da-Silva G, Teixeira NA. Cannabinoid-induced cell death in endometrial cancer cells: Involvement of TRPV1 receptors in apoptosis. J Physiol Biochem 2018; 74(2): 261-72.
[http://dx.doi.org/10.1007/s13105-018-0611-7] [PMID: 29441458]
[39]
Kaplan BLF, Springs AEB, Kaminski NE. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol 2008; 76(6): 726-37.
[http://dx.doi.org/10.1016/j.bcp.2008.06.022] [PMID: 18656454]
[40]
Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006; 39(2): 143-51.
[http://dx.doi.org/10.1080/08916930500356674] [PMID: 16698671]
[41]
Mason DR, Beck PL, Muruve DA. Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. J Innate Immun 2012; 4(1): 16-30.
[http://dx.doi.org/10.1159/000334247] [PMID: 22067846]
[42]
Franchi L, McDonald C, Kanneganti TD, Amer A, Núñez G. Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol 2006; 177(6): 3507-13.
[http://dx.doi.org/10.4049/jimmunol.177.6.3507] [PMID: 16951308]
[43]
Suryavanshi SV, Zaiachuk M, Pryimak N, Kovalchuk I, Kovalchuk O. Cannabinoids alleviate the LPS-induced cytokine storm via attenuating NLRP3 inflammasome signaling and TYK2- mediated STAT3 signaling pathways in vitro. Cells 2022; 11(9): 1391.
[http://dx.doi.org/10.3390/cells11091391] [PMID: 35563697]
[44]
Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg Med Chem 2015; 23(7): 1377-85.
[http://dx.doi.org/10.1016/j.bmc.2015.01.059] [PMID: 25703248]
[45]
Esposito G, Filippis DD, Cirillo C, et al. Cannabidiol in inflammatory bowel diseases: A brief overview. Phytother Res 2013; 27(5): 633-6.
[http://dx.doi.org/10.1002/ptr.4781] [PMID: 22815234]
[46]
Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009; 87(11): 1111-21.
[http://dx.doi.org/10.1007/s00109-009-0512-x] [PMID: 19690824]
[47]
Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012; 89(3-4): 149-55.
[http://dx.doi.org/10.1159/000336871] [PMID: 22414698]
[48]
Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis 2018; 24(4): 714-24.
[http://dx.doi.org/10.1093/ibd/izy002] [PMID: 29538683]
[49]
Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-A randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis 2019; 25(6): 1006-18.
[http://dx.doi.org/10.1093/ibd/izz017] [PMID: 31054246]
[50]
Vuolo F, Petronilho F, Sonai B, Ritter C, Hallak JE, Zuardi AW. Evaluation of serum cytokines levels and the role of cannabidiol treatment in animal model of asthma. Mediators Inflamm 2015; 2015: 538670.
[http://dx.doi.org/10.1155/2015/538670]
[51]
Vuolo F, Abreu SC, Michels M, et al. Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. Eur J Pharmacol 2019; 843: 251-9.
[http://dx.doi.org/10.1016/j.ejphar.2018.11.029] [PMID: 30481497]
[52]
Abdallah SJ, Smith BM, Ware MA, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial. Ann Am Thorac Soc 2018; 15(10): 1146-58.
[http://dx.doi.org/10.1513/AnnalsATS.201803-198OC] [PMID: 30049223]
[53]
Pickering EE, Semple SJ, Nazir MS, et al. Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety. Chron Respir Dis 2011; 8(2): 109-18.
[http://dx.doi.org/10.1177/1479972310391283] [PMID: 21436223]
[54]
Sadowska O, Baranowska-Kuczko M, Gromotowicz-Popławska A, et al. Cannabidiol ameliorates monocrotaline-induced pulmonary hypertension in rats. Int J Mol Sci 2020; 21(19): 7077.
[http://dx.doi.org/10.3390/ijms21197077] [PMID: 32992900]
[55]
Arruza L, Pazos MR, Mohammed N, et al. Cannabidiol reduces lung injury induced by hypoxic–ischemic brain damage in newborn piglets. Pediatr Res 2017; 82(1): 79-86.
[http://dx.doi.org/10.1038/pr.2017.104] [PMID: 28388598]
[56]
Khodadadi H, Salles ÉL, Jarrahi A, et al. Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis Cannabinoid Res 2020; 5(3): 197-201.
[http://dx.doi.org/10.1089/can.2020.0043] [PMID: 32923657]
[57]
Bifulco M, Fiore D, Piscopo C, Gazzerro P, Proto MC. Commentary: Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with coronavirus disease-2019. Front Pharmacol 2021; 12: 631646.
[http://dx.doi.org/10.3389/fphar.2021.631646] [PMID: 33912048]
[58]
Vidot DC, Islam JY, Marlene C-R, et al. The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States. J Addict Dis 2020; 39(1): 26-36.
[http://dx.doi.org/10.1080/10550887.2020.1811455] [PMID: 32933383]
[59]
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7(S1): 82-8.
[http://dx.doi.org/10.1177/026988119300700112] [PMID: 22290374]
[60]
Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2(3): e94.
[http://dx.doi.org/10.1038/tp.2012.15]
[61]
McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry 2018; 175(3): 225-31.
[http://dx.doi.org/10.1176/appi.ajp.2017.17030325] [PMID: 29241357]
[62]
Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018; 235(7): 1923-32.
[http://dx.doi.org/10.1007/s00213-018-4885-9] [PMID: 29619533]
[63]
Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12(5): 639-45.
[http://dx.doi.org/10.1177/1352458505070618] [PMID: 17086911]
[64]
Palmieri B, Laurino C, Vadalà M, Vadalà M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter 2019; 170(2): e93-9.
[PMID: 30993303]
[65]
Brown J, Winterstein A. Potential adverse drug events and drug- drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 2019; 8(7): 989.
[http://dx.doi.org/10.3390/jcm8070989] [PMID: 31288397]
[66]
Land MH, MacNair L, Thomas BF, Peters EN, Bonn-Miller MO. Letter to the Editor: Possible drug-drug interactions between cannabinoids and candidate COVID-19 drugs. Cannabis Cannabinoid Res 2020; 5(4): 340-3.
[http://dx.doi.org/10.1089/can.2020.0054] [PMID: 33381648]

Rights & Permissions Print Cite
Article Metrics
37
2
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy